Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2013 - 2026)

Emergent BioSolutions' Non-Current Deferred Tax Liability history runs 11 years deep, the most recent figure standing at $33.3 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 44.87% year-over-year to $33.3 million; the TTM figure through Mar 2026 stood at $33.3 million (down 44.87% YoY), while the FY2025 annual figure was $37.8 million, down 22.7% from the prior year.
• Non-Current Deferred Tax Liability was $33.3 million for Q1 2026 at Emergent BioSolutions, down from $37.8 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $125.4 million in Q4 2022 to a low of $33.3 million in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $60.7 million across 5 years, with a median of $52.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability soared 114.91% in 2022, then plunged 53.99% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $125.4 million in 2022, then tumbled by 53.03% to $58.9 million in 2023, then slipped by 16.98% to $48.9 million in 2024, then decreased by 22.7% to $37.8 million in 2025, then retreated by 11.9% to $33.3 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $33.3 million (Q1 2026), $37.8 million (Q4 2025), and $36.3 million (Q3 2025), per Business Quant data.